Federal Register / Vol. 74, No. 109 / Tuesday, June 9, 2009 / Notices 27351 

Massachusetts 01760–2447, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

Aminorex (1585) ........................... I 

Gamma Hydroxybutyric Acid 

(2010).

I 

Alpha-ethyltryptamine (7249) ....... I 

Lysergic acid diethylamide (7315) I 

Tetrahydrocannabinols (7370) ..... I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

N-Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4- 

Methylenedioxymethamphetamine (MDMA) (7405).

I 

Psilocybin (7437) .......................... I 

5-Methoxy-N,Ndiisopropyltryptamine (7439).I 

1-[1-(2- 

Thienyl)cyclohexyl]piperidine 

(TCP) (7470).

I 

1-Benzylpiperazine (BZP) (7493) I 

Heroin (9200) ............................... I 

Normorphine (9313) ..................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Nabilone (7379) ............................ II 

1-Phenylcyclohexylamine (7460) II 

Phencyclidine (7471) .................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Diprenorphine (9058) ................... II 

Ecgonine (9180) ........................... II 

Levomethorphan (9210) ............... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Metazocine (9240) ........................ II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Levo-alphacetylmethadol (9648) .. II 

Carfentanil (9743) ......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

reference standards. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Sigma Aldrich Research Biochemicals, 

Inc. to manufacture the listed basic 

classes of controlled substances is 

consistent with the public interest at 

this time. DEA has investigated Sigma 

Aldrich Research Inc. to ensure that the 

company’s registration is consistent 

with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with State and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic class of controlled substance 

listed. 

Dated: June 3, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–13358 Filed 6–8–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Registration 

By Notice dated January 9, 2009, and 

published in the Federal Register on 

January 21, 2009 (74 FR 3643), 

Mallinckrodt Inc., 3600 North Second 

Street, St. Louis, Missouri 63147, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Codeine-N-oxide (9053) ............... I 

Dihydromorphine (9145) ............... I 

Difenoxin (9168) ........................... I 

Morphine-N-oxide (9307) ............. I 

Normorphine (9313) ..................... I 

Norlevorphanol (9634) .................. I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Nabilone (7379) ............................ II 

Codeine (9050) ............................. II 

Diprenorphine (9058) ................... II 

Etorphine HCL (9059) .................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Ecgonine (9180) ........................... II 

Hydrocodone (9193) ..................... II 

Levorphanol (9220) ...................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Metopon (9260) ............................ II 

Dextropropoxyphene, bulk (9273) II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Drug Schedule 

Thebaine (9333) ........................... II 

Opium extracts (9610) .................. II 

Opium fluid extract (9620) ............ II 

Opium tincture (9630) .................. II 

Opium, powdered (9639) ............. II 

Opium, granulated (9640) ............ II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Alfentanil (9737) ........................... II 

Remifentanil (9739) ...................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The firm plans to manufacture the 

listed controlled substances for internal 

use and for sale to other companies. 

No comments or objections have been 

received. DEA has considered the 

factors in 21 U.S.C. 823(a) and 

determined that the registration of 

Mallinckrodt Inc. to manufacture the 

listed basic classes of controlled 

substances is consistent with the public 

interest at this time. DEA has 

investigated Mallinckrodt Inc. to ensure 

that the company’s registration is 

consistent with the public interest. The 

investigation has included inspection 

and testing of the company’s physical 

security systems, verification of the 

company’s compliance with state and 

local laws, and a review of the 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 823, 

and in accordance with 21 CFR 1301.33, 

the above named company is granted 

registration as a bulk manufacturer of 

the basic classes of controlled 

substances listed. 

Dated: June 3, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–13356 Filed 6–8–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Employment and Training 

Administration 

[TA–W–65,865] 

Seel Tool and Die, St. Marys, PA; 

Notice of Termination of Investigation 

Pursuant to Section 221 of the Trade 

Act of 1974, as amended, an 

investigation was initiated on April 29, 

2009, in response to a petition filed on 

behalf of workers of Seel Tool and Die, 

St. Marys, Pennsylvania. 

The petitioner has requested that the 

petition be withdrawn. Consequently, 

the investigation has been terminated.